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Summary
Background: Hp and NSAID are considered as major pathogens in peptic ulcerations and their complica-
tions but little is known about the incidence of ulcers and their complications following wide-
spread use of Hp eradication. The aims of the study were: 1) to analyze incidence of ulcers
and their complications, bleeding and perforations at time when the Hp eradication has been
used in ulcer therapy, and 2) to assess the impact of Hp infection and NSAID use on the inci-
dence of ulcers and complications.
Material/Methods: From 1996 to 2001, 381 patients with complications of peptic ulcers were admitted to the
emergency surgery, including 273 patients with bleeding ulcers and 108 with perforations out
of a sample of 6515 dyspeptic patients examined with upper endoscopy and 13C-urea breath
test (UBT).
Results: The rate of ulcer bleeding and perforations, remained relatively constant throughout the
study period. NSAID use in that group increased form 15.8% in 1999 to 19.4% in 2001. The
incidence of Hp in patients with complications assessed by UBT or CLO was 76.7%, while the
incidence of Hp in 7920 patients ranged form 72.8% in 1996 to 53.8% in 2001. There were
1940 (29.7%) patients with duodenal and/or gastric ulcer diagnosed by upper gastroscopy.
The decline in the prevalence of peptic ulcer from about 44% to 8% occurred over the same
time. A slight increase in the number of ulcer resulting from NSAID use was observed so was
the number of ulcers without Hp or NSAID (idiopathic).
Conclusions: Despite decreased Hp prevalence, the incidence of ulcers complications remained unchanged
probably due to increased use of NSAID and the appearance of idiopathic ulcers.
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BACKGROUND
Peptic ulcer hemorrhage and perforation remain
important emergency situations. Although the crucial
role of H. pylori infection in the pathogenesis of ulcer
has been generally accepted [1,2], its association with
ulcer complications is less clear. A strong argument for
the etiological role of H. pylori in ulcerogenesis is the fact
that eradication of this germ prevents the ulcer recur-
rence but it is less clear whether this therapy also
decreases the ulcer complications such as hemorrhage
and perforation [3–9]. Despite the marked progress
over last 20 years in diagnosis and treatment of ulcer
patients, especially the widespread use of the Hp eradi-
cation therapy, the mortality rate caused by hemor-
rhage and perforation worldwide is relatively stable and
averages, respectively about 10 and 7% [3–5].
The gross upper gastrointestinal bleeding is the most
common complication of peptic ulcer disease. Growing
awareness of the role of H. pylori infection in the
etiopathology of upper gastrointestinal diseases resulted
in the major change in the treatment regimens and the
widespread use of its eradication also during the emer-
gency bleeding [10].
NSAID, similarly to H. pylori, also may cause damage to
the gastric mucosa and peptic ulcers. These ulcerogens
independently and significantly increase the risk of pep-
tic ulcer and ulcer bleeding. H. pylori infection and
NSAID seem to cause the majority of bleeding ulcers
from gastrointestinal tract. Much controversy, however,
surrounds the interaction of H. pylori infection and use
of NSAID on gastro-duodenal mucosa [10–14]. The
severity of dyspeptic symptoms appears worse in infec-
ted drug users [14]. More ulcers were found in H. pylori
positive than H. pylori negative users of NSAID [12].
The complex interaction between H. pylori and NSAID
implies that it is over simplistic to conclude that their
relationship is independent, synergistic or antagonistic
without considering the influence of other factors [13]
such as previous exposure to NSAID, a history of ulcer
complication, concurrent use of acid-suppressant thera-
py, and the difference between gastrotoxicity of various
types of NSAID. Current evidence suggests that H.
pylori may contribute to an increased risk of ulcer deve-
lopment and its bleeding in patients who are about to
start NSAID treatment [14], whereas NSAID probably
account for the majority of ulcer disease in patients who
are already taking long-term NSAID [12]. Based on the
meta-analysis of numerous clinical trials, it has been
concluded that eradication of H. pylori infection reduces
the risk of ulcers for patients starting long-term NSAID
treatment [12].
The aim of this study was an attempt to analyze the inci-
dence of complications of peptic ulcer disease such as
hemorrhage and perforation, in the years 1996–2001 in
large samples of dyspeptic patients who consecutively
appeared in our H. pylori University Center for diagno-
sis and treatment of dyspeptic symptoms. The question
has been risen how these two ulcerogens – the H. pylori
and the NSAID have influenced the incidence of com-
plications of peptic ulcer disease.
MATERIAL AND METHODS
Analysis of emergency admissions for complication of
peptic ulcer was carried out in the 2nd Department of
Surgery, College of Medicine of Jagiellonian University,
Cracow between 1996 and 2001. Endoscopic and intra-
operative findings were analyzed and data from patient
history with special attention to NSAID use were
reviewed. The prevalence of H. pylori infection among
in patients with bleeding was assessed by capsulated
mini-dose 13C-urea breath test (UBT), while in those
with perforation, a biopsy sample of antral mucosa was
taken during open or laparoscopic surgery by rapid
urease test using CLO test (Delta West Pty Ltd, Bentley,
Australia).
Concomitantly the data of the Institute of Physiology,
Collegium Medicum of Jagiellonian University, Cracow,
where UBT is routinely performed, were analyzed as
described before [15]. Among all dyspeptic patients
from that group incidence of peptic ulcer disease and
use of NSAID were assessed.
During study period, 381 patients with complications of
peptic ulcers were admitted to our Department of
Surgery and this encompasses 273 patients with bleed-
ing ulcer and 108 patients with perforated ulcer. In the
same period, 7920 patients with dyspeptic symptoms
were subjected to UBT. No side-effects following the
upper endoscopy or swallowing the capsule with 13C-
urea (38 mg/capsule) were recorded in our patients with
ulcer complication or in controls without complications.
Out of these dyspeptic patients, 6515 were subjected to
upper endoscopy and most of patients with ulcer com-
plications originated from the dyspeptic patients with
gastro-duodenal ulcerations. The study was approved
by the Jagiellonian University Ethical Research Commit-
tee (KE/99/02/B/271).
RESULTS
The ratio of women to men was like 1:2 in patients with
bleeding gastric ulcer patients and this was similar to
that in non-bleeding gastric ulcer and in healthy con-
trols.
The rate of complications of peptic ulcer, namely bleed-
ing and perforations, remained relatively constant
throughout the 6 yr study period (Fig. 1).
The reported rate of NSAID use in that group
increased form 15.8% in 1999 to 19.4% in 2001 yr. The
H. pylori prevalence in patients with complications of
peptic ulcer assessed by UBT or CLO test was 76.7%
and this was not significantly different from that detec-
ted in non-bleeding gastric ulcer patients (75%) but sig-
nificantly higher than that in control healthy subjects
(60%).
In 7920 of dyspeptic patients that underwent UBT the
incidence of H. pylori infection decreased from 72.8% in
1996 to 53.8% in 2001 (Fig. 2). Among 6515 of dyspep-
tic patients who were submitted to upper endoscopy
there were 1940 (29.7%) patients with gastric ulcer
and/or duodenal ulcers. A significant decline in the
prevalence of peptic ulcer was noted from 43.7% at
1996 to only 7.7% at 2001 yr. At the same period a
slight increase in the number of ulcers resulting from
the NSAIDs use was observed (from 2.2% to 4.1%). The
number of ulcers without H. pylori and NSAID (idio-
pathic ulcers) also increased especially at 2000 and 2001
yr so the ratio of idiopathic ulcers to total number of
ulcers significantly increased during this period (Fig. 3).
DISCUSSION
This study demonstrates that during last 6 years the H.
pylori prevalence detected by UBT in Polish population
shows significant decrease from nearly 73% at 1996 to
54% at 2001. Similarly the percent of dyspeptic patients
with peptic ulcerations also showed remarkable decline
from 43.7% at 1996 to only 7.7% in 2001. At the same
time, the ratio of non-H. pylori, non-NSAID or idiopa-
thic ulcers increased from about 20% at 1996 to about
30% in 2000-2001.
The significant fall in H. pylori prevalence in our popu-
lation is closely and probably causally correlated with
the decline in the occurrence of peptic ulcerations [13]
possibly due to the improvement of living standards and
widespread use of eradication of H. pylori in the treat-
ment of peptic ulcerations.
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Figure 1. Emergency admissions for complications of peptic ulcer
(1999–2001).
Figure 3. Occurrence of gastroduodenal ulcers in dyspeptic patients with endoscopy (1996–2001). Total N = 6515, total number of ulcers =1940.
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Figure 2. Prevalence of H. pylori infection detected by UBT in dyspep-
tic patients (1996–2001). N = 7920
The major finding of this report is that despite the
decline in the H. pylori prevalence in our society and the
remarkable decline in the occurrence of peptic ulcera-
tions during last 6 years, the rate of ulcer complications
such as hemorrhages and perforations recorded in the
emergency surgery, serving for the south part of
Poland, was virtually unchanged during the same time.
One of the possible reasons for the sustained rate of
upper gastrointestinal bleeding could be an increased
use of NSAID available in this country without prescrip-
tion and sold under various names without warning of
the possible side-effects. Another explanation for the
relatively high incidence of ulcer complications is that
they may concern mostly non-H. pylori, non-NSAID
ulcers (idiopathic), whose rate was found in this study to
increase during last 6 years. Similar rise in the rate of
idiopathic ulcerations was recently reported by Xia et al.
[16] showing that about 14% among 1153 duodenal
ulcer patients had this type of ulcerations. Such ulcers
may represent serious problem due to ulcer complica-
tions such as bleeding or perforation despite the lack of
H. pylori infection and NSAID use. Further studies are
needed to establish whether these idiopathic ulcerations
tend to be accompanied by increased rate of complica-
tions such as hemorrhage or perforation.
The results of this study are at variance with the recent
report of Huang et al [12] based on meta-analysis of 16
multicenter trials showing that; 1) the H. pylori infection
acts synergistically with NSAID in promoting gastro-
duodenal ulcerations, and 2) that peptic ulcers do not
develop in patients without H. pylori infection or NSAID
use. Our finding that relatively large proportion of
ulcer patients were neither infected with H. pylori nor
used NSAID militates against the notion of Huang et al.
[12] and the reason for this discrepancy is not known.
Furthermore, according to our results based on relative-
ly large sample of ulcer patients (about 6000 patients)
examined in one unit in Poland, the H. pylori infection
actually reduced the risk of NSAID-induced gastro-duo-
denal ulcerations [13].
CONCLUSIONS
In summary, this study provides first evidence in Poland
that both the H. pylori infection and peptic ulcerations
decline in recent years, while the ulcer complications
such as hemorrhages and perforations remain at the
same level possibly due to increased use of NSAID and
the occurrence of idiopathic ulcers.
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